Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer - PubMed (original) (raw)
doi: 10.4161/cbt.8.11.8874. Epub 2009 Jun 29.
Affiliations
- PMID: 19502809
- DOI: 10.4161/cbt.8.11.8874
Free article
Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer
Agnieszka K Witkiewicz et al. Cancer Biol Ther. 2009 Jun.
Free article
Abstract
Here, we determined the possible association of stromal caveolin-1 (Cav-1) levels with DCIS recurrence and/or progression to invasive breast cancer. An initial cohort of 78 DCIS patients with follow-up data was examined. As ER-positivity was associated with recurrence, we focused our analysis on this subset of 56 patients. In this group, we observed that DCIS progressed to invasive breast cancer in approximately 14% of the patient population (8/56), in accordance with an expected progression rate of 12-15%. Nearly ninety percent of DCIS patients (7/8) that underwent recurrence to invasive breast cancer had reduced or absent levels of stromal Cav-1. Remarkably, an absence of stromal Cav-1 (score = 0) was specifically associated with early disease progression to invasive breast cancer, with reduced time to recurrence and higher recurrence rate. All DCIS patients with an absence of stromal Cav-1 underwent some form of recurrence (5/5) and the majority (4/5) underwent progression to invasive breast cancer. This represents an overall cumulative incidence rate of 100% for recurrence and 80% for progression. An absence of stromal Cav-1 in DCIS lesions was also specifically associated with the presence of inflammatory cells. Conversely, ninety-seven percent of ER(+) DCIS patients (35/36) with high levels of stromal Cav-1 (score = 2) did not show any invasive recurrence over the duration of follow-up (4-208 mo), and 89% of such patients are estimated to remain free of invasive recurrence, even after 15 y. Thus, determination of stromal Cav-1 levels may be a useful new biomarker for guiding the treatment of ER(+) DCIS patients.
Similar articles
- An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers.
Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, Kleer CG, Brody JR, Lisanti MP. Witkiewicz AK, et al. Am J Pathol. 2009 Jun;174(6):2023-34. doi: 10.2353/ajpath.2009.080873. Epub 2009 May 1. Am J Pathol. 2009. PMID: 19411448 Free PMC article. - Stromal caveolin-1 expression in breast carcinoma. Correlation with early tumor recurrence and clinical outcome.
El-Gendi SM, Mostafa MF, El-Gendi AM. El-Gendi SM, et al. Pathol Oncol Res. 2012 Apr;18(2):459-69. doi: 10.1007/s12253-011-9469-5. Epub 2011 Nov 7. Pathol Oncol Res. 2012. PMID: 22057638 - Stromal architecture and periductal decorin are potential prognostic markers for ipsilateral locoregional recurrence in ductal carcinoma in situ of the breast.
Van Bockstal M, Lambein K, Gevaert O, De Wever O, Praet M, Cocquyt V, Van den Broecke R, Braems G, Denys H, Libbrecht L. Van Bockstal M, et al. Histopathology. 2013 Oct;63(4):520-33. doi: 10.1111/his.12188. Epub 2013 Jul 26. Histopathology. 2013. PMID: 23889174 - 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.
Di Saverio S, Catena F, Santini D, Ansaloni L, Fogacci T, Mignani S, Leone A, Gazzotti F, Gagliardi S, De Cataldis A, Taffurelli M. Di Saverio S, et al. Breast Cancer Res Treat. 2008 Jun;109(3):405-16. doi: 10.1007/s10549-007-9668-7. Epub 2007 Aug 9. Breast Cancer Res Treat. 2008. PMID: 17687650 Review. - A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast.
Van Bockstal MR, Agahozo MC, Koppert LB, van Deurzen CHM. Van Bockstal MR, et al. Int J Cancer. 2020 Mar 1;146(5):1189-1197. doi: 10.1002/ijc.32362. Epub 2019 May 8. Int J Cancer. 2020. PMID: 31018242 Free PMC article. Review.
Cited by
- Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue.
Whitaker-Menezes D, Martinez-Outschoorn UE, Flomenberg N, Birbe RC, Witkiewicz AK, Howell A, Pavlides S, Tsirigos A, Ertel A, Pestell RG, Broda P, Minetti C, Lisanti MP, Sotgia F. Whitaker-Menezes D, et al. Cell Cycle. 2011 Dec 1;10(23):4047-64. doi: 10.4161/cc.10.23.18151. Epub 2011 Dec 1. Cell Cycle. 2011. PMID: 22134189 Free PMC article. - The autophagic tumor stroma model of cancer or "battery-operated tumor growth": A simple solution to the autophagy paradox.
Martinez-Outschoorn UE, Whitaker-Menezes D, Pavlides S, Chiavarina B, Bonuccelli G, Casey T, Tsirigos A, Migneco G, Witkiewicz A, Balliet R, Mercier I, Wang C, Flomenberg N, Howell A, Lin Z, Caro J, Pestell RG, Sotgia F, Lisanti MP. Martinez-Outschoorn UE, et al. Cell Cycle. 2010 Nov 1;9(21):4297-306. doi: 10.4161/cc.9.21.13817. Epub 2010 Nov 30. Cell Cycle. 2010. PMID: 21051947 Free PMC article. Review. - Caveolin-1: a multifaceted driver of breast cancer progression and its application in clinical treatment.
Qian XL, Pan YH, Huang QY, Shi YB, Huang QY, Hu ZZ, Xiong LX. Qian XL, et al. Onco Targets Ther. 2019 Feb 27;12:1539-1552. doi: 10.2147/OTT.S191317. eCollection 2019. Onco Targets Ther. 2019. PMID: 30881011 Free PMC article. Review. - Absence of caveolin-1 alters heat shock protein expression in spontaneous mammary tumors driven by Her-2/neu expression.
Ciocca DR, Cuello-Carrión FD, Natoli AL, Restall C, Anderson RL. Ciocca DR, et al. Histochem Cell Biol. 2012 Feb;137(2):187-94. doi: 10.1007/s00418-011-0879-y. Epub 2011 Nov 15. Histochem Cell Biol. 2012. PMID: 22083493 - Cancer-Associated Fibroblasts in Breast Cancer Treatment Response and Metastasis.
Fernández-Nogueira P, Fuster G, Gutierrez-Uzquiza Á, Gascón P, Carbó N, Bragado P. Fernández-Nogueira P, et al. Cancers (Basel). 2021 Jun 23;13(13):3146. doi: 10.3390/cancers13133146. Cancers (Basel). 2021. PMID: 34201840 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
- R01-CA-120876/CA/NCI NIH HHS/United States
- R01-CA-70896/CA/NCI NIH HHS/United States
- R01-CA-098779/CA/NCI NIH HHS/United States
- R01-CA-86072/CA/NCI NIH HHS/United States
- R01-CA-75503/CA/NCI NIH HHS/United States
- P30 CA056036/CA/NCI NIH HHS/United States
- R01-CA-80250/CA/NCI NIH HHS/United States
- P30-CA-56036/CA/NCI NIH HHS/United States
- R01-CA-107382/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials